AIM: To evaluate the efficacy of Myelophil, an extract containing Astragali Radix and Salviae Radix, for reducing complications induced by 5-fluorouracil (5-FU) in a gastrointestinal cancer model. METHODS: We injected 5-FU into mice and then administered Myelophil to examine the ability of the drug to treat the side effects of 5-FU in mice. Peripheral blood counts, histological examinations, and colony-forming assays of bone marrow were conducted, followed by swimming tests and assessment of survival times. RESULTS: Myelophil restored red and white blood cells and platelets in blood, and recovered cell density in bone marrow to levels comparable to those observed within the control group. In addition, Myelophil significantly increased colony-forming unit granulocyte-macrophage (CFU-GM) and CFU-erythroid (CFU-E) compared to the control group. We confirmed that interleukin-3 gene expression was upregulated by Myelophil in spleen cells. Myelophil administration also doubled the survival rate of mice that were severely myelosuppressed as a result of 5-FU injection at a lethal dose of 70%. Finally, the swimming performance of mice significantly improved as a result of Myelophil treatment. CONCLUSION: These results provide experimental evidence in support of clinical applications of Myelophil to minimize 5-FU-induced myelosuppression and improve general post-chemotherapy health.
AIM: To evaluate the efficacy of Myelophil, an extract containing Astragali Radix and Salviae Radix, for reducing complications induced by 5-fluorouracil (5-FU) in a gastrointestinal cancer model. METHODS: We injected 5-FU into mice and then administered Myelophil to examine the ability of the drug to treat the side effects of 5-FU in mice. Peripheral blood counts, histological examinations, and colony-forming assays of bone marrow were conducted, followed by swimming tests and assessment of survival times. RESULTS: Myelophil restored red and white blood cells and platelets in blood, and recovered cell density in bone marrow to levels comparable to those observed within the control group. In addition, Myelophil significantly increased colony-forming unit granulocyte-macrophage (CFU-GM) and CFU-erythroid (CFU-E) compared to the control group. We confirmed that interleukin-3 gene expression was upregulated by Myelophil in spleen cells. Myelophil administration also doubled the survival rate of mice that were severely myelosuppressed as a result of 5-FU injection at a lethal dose of 70%. Finally, the swimming performance of mice significantly improved as a result of Myelophil treatment. CONCLUSION: These results provide experimental evidence in support of clinical applications of Myelophil to minimize 5-FU-induced myelosuppression and improve general post-chemotherapy health.
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Frank M Senecal; Lorrin Yee; Nashat Gabrail; Veena Charu; Dianne Tomita; Greg Rossi; Lee Schwartzberg Journal: Clin Breast Cancer Date: 2005-12 Impact factor: 3.225
Authors: A Molassiotis; P Fernández-Ortega; D Pud; G Ozden; J A Scott; V Panteli; A Margulies; M Browall; M Magri; S Selvekerova; E Madsen; L Milovics; I Bruyns; G Gudmundsdottir; S Hummerston; A M-A Ahmad; N Platin; N Kearney; E Patiraki Journal: Ann Oncol Date: 2005-02-02 Impact factor: 32.976
Authors: B Schuell; T Gruenberger; G V Kornek; N Dworan; D Depisch; F Lang; B Schneeweiss; W Scheithauer Journal: Br J Cancer Date: 2005-10-03 Impact factor: 7.640
Authors: Jinhee Kim; You Jin Lee; Young Ah Kim; Eun-Sang Cho; Eunna Huh; Ok-Sun Bang; No Soo Kim Journal: BMC Complement Altern Med Date: 2017-08-09 Impact factor: 3.659
Authors: Katrin M Hoffmann; Robin Herbrechter; Paul M Ziemba; Peter Lepke; Leopoldo Beltrán; Hanns Hatt; Markus Werner; Günter Gisselmann Journal: Front Pharmacol Date: 2016-07-29 Impact factor: 5.810